The purpose of HTA is to provide high-quality information to decision makers about the clinical effectiveness, cost-effectiveness, and broader impact of drugs, medical technologies, and health systems.
HTAs should be a flexible process used collaboratively. The use of HTA to make reimbursement dec
A disease is defined as rare in Europe when it affects less than 1 in 2,000 citizens (Orphan Drug
A ‘one size fits all’ approach to the timing and methodology of appraisals will fail to take acco
In the EU, rare diseases that are also life-threatening or chronically debilitating with a low pr